Phibro Animal Health (NASDAQ:PAHC) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Phibro Animal Health from “strong-buy” to “buy”, while broader analyst sentiment remains cautious with an overall Hold rating and an average price target of $42.40.
• Phibro beat quarterly expectations, reporting EPS of $0.76 versus $0.72 expected and revenue of $383.5 million versus $367.0 million expected. The company also raised its FY2026 outlook, signaling continued growth momentum.
• Insider selling has been notable, with CEO Jack Bendheim disclosing a sale of 4,528 shares at $48.49 and insiders selling 182,326 shares over the past 90 days. Although the trades were made under a 10b5-1 plan, they may still weigh on investor sentiment.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Saturday.

A number of other brokerages have also commented on PAHC. Citigroup initiated coverage on shares of Phibro Animal Health in a research note on Wednesday, April 15th. They set a "neutral" rating and a $62.00 price target for the company. Zacks Research raised shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health currently has an average rating of "Hold" and an average price target of $42.40.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $40.00 on Friday. The company has a fifty day moving average of $53.90 and a 200-day moving average of $46.51. The firm has a market capitalization of $1.62 billion, a P/E ratio of 17.17, a P/E/G ratio of 0.66 and a beta of 0.61. The company has a quick ratio of 1.22, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. Phibro Animal Health has a twelve month low of $22.16 and a twelve month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.04. The business had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, sell-side analysts anticipate that Phibro Animal Health will post 3.05 EPS for the current year.

Insider Activity

In related news, CEO Jack Bendheim sold 4,528 shares of the company's stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the sale, the chief executive officer directly owned 56,152 shares in the company, valued at approximately $2,722,810.48. This represents a 7.46% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 182,326 shares of company stock valued at $9,584,712 over the last 90 days. Insiders own 50.13% of the company's stock.

Institutional Trading of Phibro Animal Health

A number of institutional investors have recently modified their holdings of PAHC. 1620 Investment Advisors Inc. increased its position in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock valued at $25,000 after buying an additional 295 shares during the period. Farther Finance Advisors LLC increased its position in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock valued at $27,000 after buying an additional 386 shares during the period. KBC Group NV bought a new stake in shares of Phibro Animal Health during the first quarter valued at about $29,000. Rothschild Investment LLC increased its position in shares of Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company's stock worth $39,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Hughes Financial Services LLC bought a new position in shares of Phibro Animal Health in the third quarter worth approximately $40,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health News Summary

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Phibro reported better-than-expected quarterly results, with EPS of $0.76 versus $0.72 expected and revenue of $383.5 million versus $367.0 million expected. Net sales rose about 10% year over year and net income increased 15%, signaling solid operating momentum. Phibro Q3 Results
• Neutral Sentiment: The company also raised its FY2026 net sales outlook to $1.46 billion-$1.50 billion and adjusted EBITDA guidance to $247 million-$255 million, which keeps the long-term growth story intact but appears to have left some investors cautious about margins and execution. FY2026 Sales & EBITDA Guidance
• Neutral Sentiment: Management will present at the Bank of America Securities Health Care Conference next week, which could provide additional clarity on the outlook and help reset investor expectations. Conference Participation
• Negative Sentiment: CEO Jack Bendheim disclosed additional stock sales, including a sale of 4,528 shares at $48.49 and a prior sale of 7,040 shares at $55.80. Although the trades were made under a pre-arranged 10b5-1 plan, multiple insider sales in a short period can still weigh on sentiment. SEC Insider Sale Filing

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.